|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Radiofrequency ablation of liver tumors: Actual limitations and potential solutions in the future显示文摘Over the past decade,radiofrequency ablation(RFA) has evolved into an important therapeutical tool for the treatment of non resectable primary and secondary liver tumors.The clinical benefit of RFA is represented in several clinical studies.They underline the safety and feasibility of this new and modern concept in treating liver tumors.RFA has proven its clinical impact not only in hepatocellular carcinoma(HCC) but also in metastatic disease such as colorectal cancer(CRC).Due to the increasing number of HCC and CRC,RFA might play an even more important role in the future.Therefore,the refinement of RFA technology is as important as the evaluation of data of prospective randomized trials that will help define guidelines for good clinical practice in RFA application in the future.The combination of hepatic resection and RFA extends the feasibility of open surgical procedures in patients with extensive tumors.Adverse effects of RFA such as biliary tract damage,liver failure and local recurrence remain an important task today but overall the long term results of RFA application in treating liver tumors are promising.Incomplete ablation of liver tumors due to insufficient technology of ablation needles,tissue cooling by the neighbouring blood vessels,large tumor masses and ablation of tumors in close vicinity to heat sensitive organs remain difficult tasks for RFA.Future solutions to overcome these limitations of RFA will include refinement of ultrasonographic guidance(accuracy of probe placement),improvements in needle technology(e.g.needles preventing charring)and intraductal cooling techniques. | Beat M Künzli Paolo Abitabile Christoph A Maurer | 2011 | World Journal of Hepatology2011，3，1： | 15 |
| 2 | Establishing proof of concept:Platelet-rich plasma and bone marrow aspirate concentrate may improve cartilage repair following surgical treatment for osteochondral lesions of the talus显示文摘Osteochondral lesions of the talus are common injuries in the athletic patient. They present a challenging clinical problem as cartilage has a poor potential for healing. Current surgical treatments consist of reparative(microfracture) or replacement(autologous osteochondral graft) strategies and demonstrate good clinical outcomes at the short and medium term follow-up. Radiological findings and second-look arthroscopy however, indicate possible poor cartilage repair with evidence of fibrous infill and fissuring of the regenerative tissue following microfracture. Longer-term follow-up echoes these findings as it demonstrates a decline in clinical outcome. The nature of the cartilage repair that occurs for an osteochondral graft to become integrated with the native surround tissue is also of concern. Studies have shown evidence of poor cartilage integration,with chondrocyte death at the periphery of the graft, possibly causing cyst formation due to synovial fluid ingress. Biological adjuncts, in the form of platelet-rich plasma(PRP) and bone marrow aspirate concentrate(BMAC), have been investigated with regard to their potential in improving cartilage repair in both in vitro and in vitro settings. The in vitro literature indicates that these biological adjuncts may increase chondrocyte proliferation as well as synthetic capability, while limiting the catabolic effects of an inflammatory joint environment. These findings have been extrapolated to in vitro animal models, with results showing that both PRP and BMAC improve cartilage repair. The basic science literature therefore establishes the proof of concept that biological adjuncts may improve cartilage repair when used in conjunction with reparative and replacement treatment strategies for osteochondral lesions of the talus. | Niall A Smyth Christopher D Murawski Amgad M Haleem Charles P Hannon Ian Savage-Elliott John G Kennedy | 2012 | World Journal of Orthopedics2012，3，7： | 8 |
| 3 | Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013显示文摘 | Marie Ng Tom Fleming Margaret Robinson Blake Thomson Nicholas Graetz Christopher Margono Erin C Mullany Stan Biryukov Cristiana Abbafati Semaw Ferede Abera Jerry P Abraham Niveen M E Abu-Rmeileh Tom Achoki Fadia S AlBuhairan Zewdie A Alemu Rafael Alfonso | 2014 | The Lancet2014，，： | 7 |
| 4 | Prediction of the severity of acute pancreatitis on admission by urinary trypsinogen activation peptide: A meta-analysis显示文摘AIM: To undertake a meta-analysis on the value of urinary trypsinogen activation peptide (uTAP) in predicting severity of acute pancreatitis on admission. METHODS: Major databases including Medline, Embase, Science Citation Index Expanded and the Cochrane Central Register of Controlled Trials in the Cochrane Library were searched to identify all relevant studies from January 1990 to January 2013. Pooled sensitivity, specificity and the diagnostic odds ratios (DORs) with 95%CI were calculated for each study and were compared to other systems/biomarkers if mentioned within the same study. Summary receiver-operating curves were conducted and the area under the curve (AUC) was evaluated. RESULTS: In total, six studies of uTAP with a cut-off value of 35 nmol/L were included in this meta-analysis. Overall, the pooled sensitivity and specificity of uTAP for predicting severity of acute pancreatitis, at time of admission, was 71% and 75%, respectively (AUC = 0.83, DOR = 8.67, 95%CI: 3.70-20.33). When uTAP was compared with plasma C-reactive protein, the pooled sensitivity, specificity, AUC and DOR were 0.64 vs 0.67, 0.77 vs 0.75, 0.82 vs 0.79 and 6.27 vs 6.32, respectively. Similarly, the pooled sensitivity, specificity, AUC and DOR of uTAPvs Acute Physiology and Chronic Health Evaluation Ⅱ within the first 48 h of admission were found to be 0.64 vs 0.69, 0.77 vs 0.61, 0.82 vs 0.73 and 6.27vs 4.61, respectively. CONCLUSION: uTAP has the potential to act as a stratification marker on admission for differentiating disease severity of acute pancreatitis. | Wei Huang Kiran Altaf Tao Jin Jun-Jie Xiong Li Wen Muhammad A Javed Marianne Johnstone Ping Xue Christopher M Halloran Qing Xia | 2013 | World Journal of Gastroenterology2013，19，28： | 7 |
| 5 | Risk stratification for ST segment elevation myocardial infarction in the era of primary percutaneous coronary intervention显示文摘Acute coronary syndromes presenting with ST elevation are usually treated with emergency reperfusion/revascularisation therapy. In contrast current evidence and national guidelines recommend risk stratification for non ST segment elevation myocardial infarction(NSTEMI) with the decision on revascularisation dependent on perceived clinical risk. Risk stratification for STEMI has no recommendation. Statistical risk scoring techniques in NSTEMI have been demonstrated to improve outcomes however their uptake has been poor perhaps due to questions over their discrimination and concern for application to individuals who may not have been adequately represented in clinical trials. STEMI is perceived to carry sufficient risk to warrant emergency coronary intervention [by primary percutaneous coronary intervention(PPCI)] even if this results in a delay to reperfusion with immediate thrombolysis. Immediate thrombolysis may be as effective in patients presenting early, or at low risk, but physicians are poor at assessing clinical and procedural risks and currently are not required to consider this. Inadequate data on risk stratification in STEMI inhibits the option of immediate fibrinolysis, which may be cost-effective. Currently the mode of reperfusion for STEMI defaults to emergency angiography and percutaneous coronary intervention ignoring alternative strategies. This review article examines the current risk scores and evidence base for risk stratification for STEMI patients. The requirements for an ideal STEMI risk score are discussed. | Richard A Brogan Christopher J Malkin Philip D Batin Alexander D Simms James M McLenachan Christopher P Gale | 2014 | World Journal of Cardiology2014，6，8： | 6 |
| 6 | Liver resections can be performed safely without Pringle maneuver: A prospective study显示文摘AIM To evaluate liver resections without Pringle maneuver, i.e., clamping of the portal triad. METHODS Between 9/2002 and 7/2013, 175 consecutive liver resections(n = 101 major anatomical and n = 74 large atypical > 5 cm) without Pringle maneuver were performed in 127 patients(143 surgeries). Accompanying, 37 wedge resections(specimens < 5 cm) and 43 radiofrequency ablations were performed. Preoperative volumetric calculation of the liver remnant preceeded all anatomical resections. The liver parenchyma was dissected by waterjet. The median central venous pressure was 4 mmH g(range: 5-14). Data was collected prospectively. RESULTS The median age of patients was 60 years(range: 16-85). Preoperative chemotherapy was used in 70 cases(49.0%). Liver cirrhosis was present in 6.3%, and liver steatosis of ≥ 10% in 28.0%. Blood loss was median 400 mL(range 50-5000 mL). Perioperative blood transfusions were given in 22/143 procedures(15%). The median weight of anatomically resected liver specimens was 525 g(range: 51-1850 g). One patient died postoperatively. Biliary leakages(n = 5) were treated conservatively. Temporary liver failure occurred in two patients.CONCLUSION Major liver resections without Pringle maneuver are feasible and safe. The avoidance of liver inflow clamping might reduce liver damage and failure, and shorten the hospital stay. | Christoph A Maurer Mikolaj Walensi Samuel A Kaser Beat M Künzli Rene Lotscher Anne Zuse | 2016 | World Journal of Hepatology2016，8，24： | 6 |
| 7 | National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants显示文摘 | Goodarz Danaei Mariel M Finucane Yuan Lu Gitanjali M Singh Melanie J Cowan Christopher J Paciorek John K Lin Farshad Farzadfar Young-Ho Khang Gretchen A Stevens Mayuree Rao Mohammed K Ali Leanne M Riley Carolyn A Robinson Majid Ezzati | 2011 | The Lancet2011，，9785： | 6 |
| 8 | Clinical outcomes following salvage Gamma Knife radiosurgery for recurrent glioblastoma显示文摘Glioblastoma multiforme(GBM) is the most common malignant primary brain tumor with a survival prognosis of 14-16 mo for the highest functioning patients. Despite aggressive, multimodal upfront therapies, the majority of GBMs will recur in approximately six months. Salvage therapy options for recurrent GBM(r GBM) are an area of intense research. This study compares recent survival and quality of life outcomes following Gamma Knife radiosurgery(GKRS) salvage therapy. Following a Pub Med search for studies usingGKRS as salvage therapy for malignant gliomas, nine articles from 2005 to July 2013 were identified which evaluated rG BM treatment. In this review, we compare overall survival following diagnosis, overall survival following salvage treatment, progression-free survival, time to recurrence, local tumor control, and adverse radiation effects. This report discusses results for rG BM patient populations alone, not for mixed populations with other tumor histology grades. All nine studies reported median overall survival rates(from diagnosis, range:16.7-33.2 mo; from salvage, range:9-17.9 mo). Three studies identified median progression-free survival(range:4.6-14.9 mo). Two showed median time to recurrence of GBM. Two discussed local tumor control. Six studies reported adverse radiation effects(range:0%-46% of patients). The greatest survival advantages were seen in patients who received GKRS salvage along with other treatments, like resection or bevacizumab, suggesting that appropriately tailored multimodal therapy should be considered with each rG BM patient. However, there needs to be a randomized clinical trial to test GKRS for rG BM before the possibility of selection bias can be dismissed. | Erik W Larson Halloran E Peterson Wayne T Lamoreaux Alexander R MacKay Robert K Fairbanks Jason A Call Jonathan D Carlson Benjamin C Ling John J Demakas Barton S Cooke Christopher M Lee | 2014 | World Journal of Clinical Oncology2014，5，2： | 5 |
| 9 | Gastric intestinal metaplasia is associated with gastric dysplasia but is inversely correlated with esophageal dysplasia显示文摘AIM To determine which clinical factors might be associated with gastric intestinal metaplasia(IM) in a North American population.METHODS Pathology and endoscopy databases at an academicmedical center were reviewed to identify patients with and without gastric IM on biopsies for a retrospective cohort study. Patient demographics, insurance status, and other clinical factors were reviewed.RESULTS Four hundred and sixty-eight patients with gastric IM(mean age: 61.0 years ± 14.4 years, 55.5% female) and 171 without gastric IM(mean age: 48.8 years ± 20.8 years, 55.0% female) were compared. The endoscopic appearance of atrophic gastritis correlated with finding gastric IM on histopathology(OR = 2.05, P = 0.051). Gastric IM was associated with histologic findings of chronic gastritis(OR = 2.56, P < 0.001), gastric ulcer(OR = 6.97, P = 0.015), gastric dysplasia(OR = 6.11, P = 0.038), and gastric cancer(OR = 6.53, P = 0.027). Histologic findings of Barrett's esophagus(OR = 0.28, P = 0.003) and esophageal dysplasia(OR = 0.11, P = 0.014) were inversely associated with gastric IM. Tobacco use(OR = 1.73, P = 0.005) was associated with gastric IM.CONCLUSION Patients who smoke or have the endoscopic finding of atrophic gastritis are more likely to have gastric IM and should have screening gastric biopsies during esophagogastroduodenoscopy(EGD). Patients with gastric IM are at increased risk for having gastric dysplasia and cancer, and surveillance EGD with gastric biopsies in these patients might be reasonable. | Justin M Gomez James T Patrie Wissam Bleibel Jeanetta W Frye Bryan G Sauer Vanessa M Shami Edward B Stelow Christopher A Moskaluk Andrew Y Wang | 2017 | World Journal of Gastrointestinal Endoscopy2017，9，2： | 3 |
| 10 | Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/Ipr mouse model of systemic lupus erythematosus显示文摘热吃惊蛋白质 90 的提高的表示(HSP90 ) 在全身的豺狼座 erythematosus (SLE ) 的肾和浆液被发现了病人和 MRL/Mp-Fas lpr /Fas lpr (MRL/lpr ) 自体免疫的老鼠。如果 HSP90 的抑制将在 MRL/lpr 老鼠减少疾病,我们调查了。在在 vivo 的 vitro,有在 IL-6 的有免疫力刺激的显示出的减少的表示以前的 HSP90 禁止者 Geldanamycin 的 mesangial 房间的预告的处理, IL-12 和号码,我们发现当与 C57BL/6 相比鼠标和 MRL/lpr 鼠标与 HSP90 禁止者 17-DMAG 对待时, HSP90 表示在 MRL/lpr 肾被提高。与 17-DMAG 对待的 MRL/lpr 老鼠显示出减少的 proteinuria 并且减少了浆液 anti-dsDNA 抗体生产。Glomerulonephritis 和 glomerular IgG 和 C3 没被 17-DMAG 的管理显著地在 MRL/lpr 影响。17-DMAG 增加了 CD8 + T 房间,减少的双 negative T 房间,减少 CD4/CD8 比率和减少的小囊的 B 房间。这些研究建议 HSP90 可以在调整 T 房间区别和激活起一个作用并且 HSP90 抑制可以在豺狼座减少发炎。 | Samuel K Shimp III Cristen B Chafin Nicole L Regna Sarah E Hammond Molly A Read David L Caudell Marissa Nichole Rylander Christopher M Reilly | 2012 | Cellular & Molecular Immunology2012，9，3： | 3 |
| 11 | 一种房颤风险评分系统的建立(Framingham心脏研究):基于社区的队列研究显示文摘背景房颤导致了发病率和病死率的显著上升。本研究旨在建立一种预测个体罹患房颤绝对风险的风险评分系统,并提供研究人员评价新危险因素的流程。方法作者评估了Framingham心脏研究中于1968年6月至1987年9月间进行了8044次检测的4764例参与者(55%为女性,年龄45~95岁)。此后,参与者被随访至房颤首发,随访期最长达10年。多变量Coxi回归确认出1(1年内罹患房颤的临床危险因素。次级分析纳入了常规超声心动图检测指标(5152例4参与者,7156次检测)对房颤风险进行再分层评估,并评价超声检测指标能否提高风险预测能力。结果4764例参与者中的457例4(10%)罹患房颤。年龄、性别、体重指数、收缩压、降压治疗、PR间期、有临床意义的心脏杂音及心力衰竭与房颤相关,并被纳入了风险评分模型(除体重指数P=0.08外,其余均为P〈0.05),模型的C统计量为0.78(95%CI0.76~0.80)。10年房颤风险随年龄变化:年龄〈65岁的人群中53例(1%)风险高于15%,而〉65岁的人群中为783例(27%)。为提高预测能力而纳入超声检测指标仅使模型C统计量略微增高,由0.78(95%C10.75~0.80)增至0.79(95%CI0.77~0.82:P=0.005)。超声心动图检测指标并不能改善风险再分层评估(P=0.18)。结论基于社区医疗中易得的临床因素建立的风险评分系统,有助于确认社区个体罹患房颤的风险,评估技术或标志物能否改善风险预测,以及针对高危个体采取预防措施。 | Renate B Schnabel Lisa M Sullivan Daniel Levy Michael J Pencina Joseph M Massaro Ralph B D'Agostino Sr Christopher Newton-Cheh Jennifer F Yamamoto Jared W Magnani Thomas M Tadros William B Kannel Thomas J Wang Patrick T Ellinor Philip A Wolf Ramachanclran S Vasan Emelia J Benjamin 黄刚(译) | 2009 | 世界临床医学2009，，9： | 2 |
| 12 | Animal models of ex vivo lung perfusion as a platform for transplantation research显示文摘Ex vivo lung perfusion(EVLP) is a powerful experimental model for isolated lung research. EVLP allows for the lungs to be manipulated and characterized in an external environment so that the effect of specific ventilation/perfusion variables can be studied independent of other confounding physiologic contributions. At the same time,EVLP allows for normal organ level function and real-time monitoring of pulmonary physiology and mechanics. As a result,this technique provides uniqueadvantages over in vivo and in vitro models. Small and large animal models of EVLP have been developed and each of these models has their strengths and weaknesses. In this manuscript,we provide insight into the relative strengths of each model and describe how the development of advanced EVLP protocols is leading to a novel experimental platform that can be used to answer critical questions in pulmonary physiology and transplant medicine. | Kevin Nelson Christopher Bobba Samir Ghadiali Don Hayes Jr Sylvester M Black Bryan A Whitson | 2014 | World Journal of Experimental Medicine2014，4，2： | 2 |
| 13 | Microstructural analysis of pineal volume using trueFISP imaging显示文摘AIM:To determine the spectrum of pineal microstructures (solid/cystic parts) in a large clinical population using a high-resolution 3D-T2-weighted sequence. METHODS:A total of 347 patients enrolled for cranial magnetic resonance imaging were randomly included in this study. Written informed consent was obtained from all patients. The exclusion criteria were artifacts or mass lesions prohibiting evaluation of the pineal gland in any of the sequences. True-FISP-3D-imaging (1.5-T, isotropic voxel 0.9 mm) was performed in 347 adults (55.4 ± 18.1 years). Pineal gland volume (PGV), cystic volume, and parenchyma volume (cysts exclud- ed) were measured manually. RESULTS:Overall, 40.3% of pineal glands were cystic. The median PGV was 54.6 mm 3 (78.33 ± 89.0 mm 3 ), the median cystic volume was 5.4 mm 3 (15.8 ± 37.2mm 3 ), and the median parenchyma volume was 53.6 mm 3 (71.9 ± 66.7 mm 3 ). In cystic glands, the standard deviation of the PGV was substantially higher than in solid glands (98% vs 58% of the mean). PGV declined with age (r = -0.130, P = 0.016). CONCLUSION:The high interindividual volume variation is mainly related to cysts. Pineal parenchyma volume decreased slightly with age, whereas genderrelated effects appear to be negligible. | Jan M Bumb Marc A Brockmann Christoph Groden Ingo Nolteb | 2013 | World Journal of Radiology2013，5，4： | 2 |
| 14 | Statin use and cognitive function in middle-aged adults with type 1 diabetes显示文摘AIM To test associations between statin use and cognitive impairment in adults with childhood-onset type 1 diabetes(T1D).METHODS In 2010-13, n = 108 middle-aged participants from ongoing observational Pittsburgh Epidemiology of Diabetes Complications Study underwent neurocognitive assessment(mean age and T1 D duration of 49 and 41 years, respectively). All were diagnosed with childhoodonset(i.e., prior to age 18) T1 D between 1950 and 1980 and were seen within one year of diagnosis at Children's Hospital of Pittsburgh. Self-reported statin use(yes/no and if yes, name of statin) was collected biennially from parent study baseline(1986-1988) to time of neurocognitive testing. Logistic regression models tested associations between statin use groups and cognitive impairment(defined as having two or more cognitive test scores 1.5SD or worse than published norms) while linear regression models tested associations between statin use groups and cognitive domain z-scores(domains: Verbal IQ, memory, executive function, psychomotor speed, and visuo-construction). All models controlled for education and age. To address confounding by indication, models were repeated using a propensity score for statin use.RESULTS Of the 108 participants, 51 reported never using statins. Median duration of statin use among the 57 ever users was 6 years. These 57 ever statin users were split to create two groups(≤ or > median years of statin use): 1-6 years(n = 25), and 7-12 years(n = 32). Compared with never users, using statins 1-6 years tripled the odds of cognitive impairment(OR = 3.16; 95%CI: 0.93-10.72; P = 0.06) and using statins 7-12 years almost quintupled the odds of cognitive impairment(OR = 4.84; 95%CI: 1.63-14.44; P = 0.005). Compared with never users, using statins 1-6 or 7-12 years was related to worse performance in the memory domain(β =-0.52; P = 0.003, and-0.39; P = 0.014, respectively). Adjusting for coronary artery disease, low density lipoprotein cholesterol, and Apo E4 status did not substantially alter results, and none of these covariates were significantly related to cognitive outcomes(all P > 0.05). Propensity score analyses support that associations between poor cognitive outcomes and statin use were not due merely to confounding by indication. CONCLUSION Statin use was associated with cognitive impairment, particularly affecting memory, in these middle-aged adults with childhood-onset T1 D, whom at this age, should not yet manifest age-related memory deficits. | Karen A Nunley Trevor J Orchard Christopher M Ryan Rachel Miller Tina Costacou Caterina Rosano | 2017 | World Journal of Diabetes2017，8，6： | 2 |
| 15 | Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy显示文摘 | Sinha Rohit Anthony You Seo-Hee Zhou Jin Siddique Mobin M Bay Boon-Huat Zhu Xuguang Privalsky Martin L Cheng Sheue-Yann Stevens Robert D Summers Scott A Newgard Christopher B Lazar Mitchell A Yen Paul M | 2012 | EN2012，，7： | 2 |
| 16 | 临床试验数据共享声明国际医学期刊编辑委员会统一要求显示文摘国际医学期刊编辑委员会(ICMJE)认为,由于临床试验参与者处于研究风险之中,我们有伦理义务来负责任地共享干预性临床试验产生的原始数据。2016年1月,ICMJE发表了1项关于临床试验数据共享的提案,旨在帮助创造共享去标识个体患者数据的常态化环境。迄今,应我们的反馈要求,ICMJE收到了很多来自个人和团体的意见。 | Darren B Taichman Peush Sahni Larry Peiperl Christine Laine Astrid James Sung-Tae Hong Abraham Haileamlak Laragh Gollogly Fiona Godlee Frank A Frizelle Fernando Florenzano Jeffrey M Drazen Howard Bauchner Christopher Baethge Deutsches Arzteblatt Joyce Backus 季媛媛 | 2017 | 英国医学杂志中文版2017，20，7： | 2 |
| 17 | Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis显示文摘 | John A Green John M Kirwan Jayne F Tierney Paul Symonds Lydia Fresco Mandy Collingwood Christopher J Williams | 2001 | The Lancet . 2001 (9284)2001，，： | 2 |
| 18 | 临床试验数据共享声明显示文摘国际医学期刊编辑委员会(ICMJE)认为,由于临床试验参与者处于研究风险之中,我们有伦理义务来负责任地共享干预性临床试验产生的原始数据。2016年1月,ICMJE发表了一项关于临床试验数据共享的提案,旨在帮助创造共享去标识个体患者数据的常态化环境。 | Darren B Taichman Peush Sahni Anja Pinborg Larry Peiperl Christine Laine Astrid James Sung-Tae Hong Abraham Haileamlak Laragh Gollogly Fiona Godlee Frank A Frizelle Fernando Florenzano Jeffrey M Drazen Howard Bauchner Christopher Baethge Joyce Backus 季媛媛 | 2017 | 中国医院院长2017，13，16： | 2 |
| 19 | National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants显示文摘 | Goodarz Danaei Mariel M Finucane Yuan Lu Gitanjali M Singh Melanie J Cowan Christopher J Paciorek John K Lin Farshad Farzadfar Young-Ho Khang Gretchen A Stevens Mayuree Rao Mohammed K Ali Leanne M Riley Carolyn A Robinson Majid Ezzati | 2011 | The Lancet2011，，9785： | 2 |
| 20 | National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants显示文摘 | Goodarz Danaei Mariel M Finucane Yuan Lu Gitanjali M Singh Melanie J Cowan Christopher J Paciorek John K Lin Farshad Farzadfar Young-Ho Khang Gretchen A Stevens Mayuree Rao Mohammed K Ali Leanne M Riley Carolyn A Robinson Majid Ezzati | 2011 | 2011 (9785)2011，，9785： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员